NeuroDirect™ Ketamine
Post-Traumatic Stress Disorder (PTSD)
Phase 1Active
Key Facts
Indication
Post-Traumatic Stress Disorder (PTSD)
Phase
Phase 1
Status
Active
Company
About Psycheceutical Bioscience
Psycheceutical Bioscience is a private, pre-revenue biotech founded in 2019, pioneering a novel topical drug delivery system for psychedelic medicines. The company's NeuroDirect™ technology, applied at the back of the neck, is designed to deliver compounds like ketamine directly to neural targets, aiming to reduce systemic side effects such as hallucinations and improve dosing control. Its lead program, NeuroDirect™ Ketamine for PTSD, is in Phase 1 clinical trials, positioning the company at the intersection of the growing psychedelics therapeutics and advanced drug delivery markets. The company is headquartered in Miami, Florida.
View full company profileTherapeutic Areas
Other Post-Traumatic Stress Disorder (PTSD) Drugs
| Drug | Company | Phase |
|---|---|---|
| AL001 | Alzamend Neuro | Preclinical |
| PES200 | Virpax Pharmaceuticals | Discovery/Preclinical |
| Sequential Dialysis Technique | Halberd | Discovery |
| Sana Device for PTSD | Sana Health | Pilot/Proof-of-Concept |
| MDMA-assisted therapy | Lykos Therapeutics | Phase 3 |
| Neuroplastogen Programs | Delix Therapeutics | Pre-clinical |
| TSND-201 (Methylone) | Transcend Therapeutics | Phase 2 |
| Phoenix CR | Evren Technologies | Unknown |
| Lu AG09222 | Lundbeck | Phase 2 |
| COMP360 Psilocybin Therapy | Compass Pathways | Phase 2 |
| NRX-101 | NRx Pharmaceuticals | Phase 2 |
| Ketamir-2 (Ketamir) | MIRA Pharmaceuticals | Phase 1 |